Carasent Croissance future

Future contrôle des critères 4/6

Carasent devrait augmenter ses bénéfices et son chiffre d'affaires de 78.6% et de 18% par an respectivement. Le BPA devrait croître de de 78.7% par an. Le rendement des capitaux propres devrait être 4.5% dans 3 ans.

Informations clés

78.6%

Taux de croissance des bénéfices

78.7%

Taux de croissance du BPA

Healthcare Services croissance des bénéfices	27.6%
Taux de croissance des recettes	18.0%
Rendement futur des capitaux propres	4.5%
Couverture par les analystes	Low
Dernière mise à jour	31 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:C34 - Estimations futures des analystes et données financières antérieures (NOK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	410	46	55	106	2
12/31/2025	364	27	39	88	2
12/31/2024	280	-18	-80	38	2
9/30/2024	265	-8	-25	25	N/A
6/30/2024	254	-10	-33	19	N/A
3/31/2024	251	-56	-61	-4	N/A
12/31/2023	244	-46	-74	-4	N/A
9/30/2023	235	-64	-86	-3	N/A
6/30/2023	227	-49	-83	10	N/A
3/31/2023	210	5	-71	27	N/A
12/31/2022	195	31	-58	34	N/A
9/30/2022	179	47	-40	37	N/A
6/30/2022	168	15	-29	36	N/A
3/31/2022	154	33	-3	47	N/A
12/31/2021	137	0	-6	32	N/A
9/30/2021	117	-33	-1	29	N/A
6/30/2021	98	-21	11	33	N/A
3/31/2021	83	-46	2	21	N/A
12/31/2020	71	-38	3	19	N/A
9/30/2020	64	-14	5	21	N/A
6/30/2020	58	-4	3	18	N/A
3/31/2020	52	3	1	15	N/A
12/31/2019	48	3	2	12	N/A
9/30/2019	44	2	2	11	N/A
6/30/2019	40	0	1	7	N/A
3/31/2019	35	-3	-3	2	N/A
12/31/2018	24	-7	-2	0	N/A
9/30/2018	14	12	30	31	N/A
6/30/2018	6	18	N/A	52	N/A
3/31/2018	N/A	19	N/A	52	N/A
12/31/2017	N/A	20	N/A	51	N/A
9/30/2017	25	128	N/A	-6	N/A
6/30/2017	79	131	N/A	-16	N/A
3/31/2017	136	139	N/A	-24	N/A
12/31/2016	194	142	N/A	-36	N/A
9/30/2016	205	3	N/A	-33	N/A
6/30/2016	234	56	N/A	-60	N/A
3/31/2016	259	56	N/A	-42	N/A
12/31/2015	305	61	N/A	-32	N/A
9/30/2015	322	-31	N/A	4	N/A
6/30/2015	307	-80	N/A	24	N/A
3/31/2015	314	-84	N/A	22	N/A
12/31/2014	294	-79	N/A	24	N/A
9/30/2014	255	2	N/A	25	N/A
6/30/2014	248	2	N/A	23	N/A
3/31/2014	246	3	N/A	23	N/A
12/31/2013	254	5	N/A	29	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: C34 devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 1% ).

Bénéfices vs marché: C34 devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: C34 devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de C34 ( 18% par an) devrait croître plus rapidement que le marché German ( 5.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de C34 ( 18% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de C34 devrait être faible dans 3 ans ( 4.5 %).

Carasent Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance